High-dose budesonide for early COVID-19 - Authors' reply
| Errataetall: |
CommentOn: Lancet. 2021 Sep 4;398(10303):843-855. - PMID 34388395 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:398 |
|---|---|
| Enthalten in: |
Lancet (London, England) - 398(2021), 10317 vom: 11. Dez., Seite 2147-2148 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hobbs, F D Richard [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
51333-22-3 |
|---|
| Anmerkungen: |
Date Completed 23.12.2021 Date Revised 06.03.2024 published: Print CommentOn: Lancet. 2021 Sep 4;398(10303):843-855. - PMID 34388395 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S0140-6736(21)02449-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334320194 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334320194 | ||
| 003 | DE-627 | ||
| 005 | 20240306232052.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(21)02449-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM334320194 | ||
| 035 | |a (NLM)34895528 | ||
| 035 | |a (PII)S0140-6736(21)02449-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hobbs, F D Richard |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High-dose budesonide for early COVID-19 - Authors' reply |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.12.2021 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Lancet. 2021 Sep 4;398(10303):843-855. - PMID 34388395 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 650 | 7 | |a Budesonide |2 NLM | |
| 650 | 7 | |a 51333-22-3 |2 NLM | |
| 650 | 7 | |a Formoterol Fumarate |2 NLM | |
| 650 | 7 | |a W34SHF8J2K |2 NLM | |
| 700 | 1 | |a Yu, Ly-Mee |e verfasserin |4 aut | |
| 700 | 1 | |a Saville, Benjamin R |e verfasserin |4 aut | |
| 700 | 1 | |a Bafadhel, Mona |e verfasserin |4 aut | |
| 700 | 1 | |a Butler, Christopher C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lancet (London, England) |d 1945 |g 398(2021), 10317 vom: 11. Dez., Seite 2147-2148 |w (DE-627)NLM000473936 |x 1474-547X |7 nnns |
| 773 | 1 | 8 | |g volume:398 |g year:2021 |g number:10317 |g day:11 |g month:12 |g pages:2147-2148 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0140-6736(21)02449-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 398 |j 2021 |e 10317 |b 11 |c 12 |h 2147-2148 | ||